Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

GlaxoSmithKline Plc 's ViiV Healthcare announces US FDA approved Triumeq


Tuesday, 26 Aug 2014 02:19am EDT 

ViiV Healthcare:Announced that US Food and Drug Administration (FDA) has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for treatment of HIV-1 infection.1.Says Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV option of single-pill regimen, combines integrase strand transfer inhibitor (INSTI) dolutegravir, with nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.ViiV Healthcare is a global specialist HIV company established in Nov. 2009 by GlaxoSmithKline and Pfizer.Says Triumeq alone is not recommended for use in patients with current or past history of resistance to any components of Triumeq.Triumeq alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected INSTI resistance because the dose of dolutegravir in Triumeq is insufficient in these populations.Before initiating treatment with abacavir-containing products, screening for presence of genetic marker, the HLA-B*5701 allele, should be performed in any HIV-infected patient, irrespective of racial origin.Products containing abacavir should not be used in patients known to carry the HLA-B*5701 allele .1. 

Company Quote

43.29
1.25 +2.97%
18 Dec 2014